Vir Biotechnology Inc
NASDAQ:VIR

Watchlist Manager
Vir Biotechnology Inc Logo
Vir Biotechnology Inc
NASDAQ:VIR
Watchlist
Price: 7.12 USD 2.45% Market Closed
Market Cap: 980.6m USD
Have any thoughts about
Vir Biotechnology Inc?
Write Note

Intrinsic Value

VIR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VIR stock under the Base Case scenario is 1.74 USD. Compared to the current market price of 7.12 USD, Vir Biotechnology Inc is Overvalued by 75%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VIR Intrinsic Value
1.74 USD
Overvaluation 75%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vir Biotechnology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VIR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VIR?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Vir Biotechnology Inc

Provide an overview of the primary business activities
of Vir Biotechnology Inc.

What unique competitive advantages
does Vir Biotechnology Inc hold over its rivals?

What risks and challenges
does Vir Biotechnology Inc face in the near future?

Has there been any significant insider trading activity
in Vir Biotechnology Inc recently?

Summarize the latest earnings call
of Vir Biotechnology Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vir Biotechnology Inc.

Provide P/S
for Vir Biotechnology Inc.

Provide P/E
for Vir Biotechnology Inc.

Provide P/OCF
for Vir Biotechnology Inc.

Provide P/FCFE
for Vir Biotechnology Inc.

Provide P/B
for Vir Biotechnology Inc.

Provide EV/S
for Vir Biotechnology Inc.

Provide EV/GP
for Vir Biotechnology Inc.

Provide EV/EBITDA
for Vir Biotechnology Inc.

Provide EV/EBIT
for Vir Biotechnology Inc.

Provide EV/OCF
for Vir Biotechnology Inc.

Provide EV/FCFF
for Vir Biotechnology Inc.

Provide EV/IC
for Vir Biotechnology Inc.

Show me price targets
for Vir Biotechnology Inc made by professional analysts.

What are the Revenue projections
for Vir Biotechnology Inc?

How accurate were the past Revenue estimates
for Vir Biotechnology Inc?

What are the Net Income projections
for Vir Biotechnology Inc?

How accurate were the past Net Income estimates
for Vir Biotechnology Inc?

What are the EPS projections
for Vir Biotechnology Inc?

How accurate were the past EPS estimates
for Vir Biotechnology Inc?

What are the EBIT projections
for Vir Biotechnology Inc?

How accurate were the past EBIT estimates
for Vir Biotechnology Inc?

Compare the revenue forecasts
for Vir Biotechnology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vir Biotechnology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vir Biotechnology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vir Biotechnology Inc compared to its peers.

Compare the P/E ratios
of Vir Biotechnology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Vir Biotechnology Inc with its peers.

Analyze the financial leverage
of Vir Biotechnology Inc compared to its main competitors.

Show all profitability ratios
for Vir Biotechnology Inc.

Provide ROE
for Vir Biotechnology Inc.

Provide ROA
for Vir Biotechnology Inc.

Provide ROIC
for Vir Biotechnology Inc.

Provide ROCE
for Vir Biotechnology Inc.

Provide Gross Margin
for Vir Biotechnology Inc.

Provide Operating Margin
for Vir Biotechnology Inc.

Provide Net Margin
for Vir Biotechnology Inc.

Provide FCF Margin
for Vir Biotechnology Inc.

Show all solvency ratios
for Vir Biotechnology Inc.

Provide D/E Ratio
for Vir Biotechnology Inc.

Provide D/A Ratio
for Vir Biotechnology Inc.

Provide Interest Coverage Ratio
for Vir Biotechnology Inc.

Provide Altman Z-Score Ratio
for Vir Biotechnology Inc.

Provide Quick Ratio
for Vir Biotechnology Inc.

Provide Current Ratio
for Vir Biotechnology Inc.

Provide Cash Ratio
for Vir Biotechnology Inc.

What is the historical Revenue growth
over the last 5 years for Vir Biotechnology Inc?

What is the historical Net Income growth
over the last 5 years for Vir Biotechnology Inc?

What is the current Free Cash Flow
of Vir Biotechnology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vir Biotechnology Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vir Biotechnology Inc

Current Assets 1B
Cash & Short-Term Investments 914.5m
Other Current Assets 132.7m
Non-Current Assets 451.2m
Long-Term Investments 271.5m
PP&E 125.6m
Intangibles 36.2m
Other Non-Current Assets 17.9m
Current Liabilities 117.2m
Accounts Payable 7.3m
Accrued Liabilities 94.7m
Other Current Liabilities 15.2m
Non-Current Liabilities 140.5m
Other Non-Current Liabilities 140.5m
Efficiency

Earnings Waterfall
Vir Biotechnology Inc

Revenue
78.6m USD
Cost of Revenue
-959k USD
Gross Profit
77.7m USD
Operating Expenses
-647.8m USD
Operating Income
-570.1m USD
Other Expenses
36.7m USD
Net Income
-533.3m USD

Free Cash Flow Analysis
Vir Biotechnology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VIR Profitability Score
Profitability Due Diligence

Vir Biotechnology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 3-Year Average ROE
Low 3-Year Average ROIC
26/100
Profitability
Score

Vir Biotechnology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

VIR Solvency Score
Solvency Due Diligence

Vir Biotechnology Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
63/100
Solvency
Score

Vir Biotechnology Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VIR Price Targets Summary
Vir Biotechnology Inc

Wall Street analysts forecast VIR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VIR is 30.09 USD with a low forecast of 10.1 USD and a high forecast of 115.5 USD.

Lowest
Price Target
10.1 USD
42% Upside
Average
Price Target
30.09 USD
323% Upside
Highest
Price Target
115.5 USD
1 522% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VIR?

Click here to dive deeper.

Dividends

Vir Biotechnology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VIR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VIR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VIR News

Other Videos

Profile

Vir Biotechnology Inc Logo
Vir Biotechnology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

973.3m USD

Dividend Yield

0%

Description

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.

Contact

CALIFORNIA
San Francisco
499 Illinois St Ste 500
+14159064324.0
www.vir.bio

IPO

2019-10-11

Employees

444

Officers

CEO & Director
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Executive VP & Chief Technology Officer
Dr. Ann M. Hanly Ph.D.
Executive VP & Chief Business Officer
Dr. Jeff Calcagno M.D.
Co-Founder & Scientific Advisor
Dr. Louis J. Picker M.D.
Executive VP & CFO
Mr. Jason O'Byrne
Senior VP, Principal Accounting Officer & Chief Accounting Officer
Mr. Brent Sabatini
Show More
Executive VP & Chief Scientific Officer
Dr. Jennifer Eileen Towne Ph.D.
Vice President of Investor Relations
Ms. Heather Rowe Armstrong
Show Less

See Also

Discover More
What is the Intrinsic Value of one VIR stock?

The intrinsic value of one VIR stock under the Base Case scenario is 1.74 USD.

Is VIR stock undervalued or overvalued?

Compared to the current market price of 7.12 USD, Vir Biotechnology Inc is Overvalued by 75%.

Back to Top